149 related articles for article (PubMed ID: 36774856)
21. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Yamada T; Hirai S; Katayama Y; Yoshimura A; Shiotsu S; Watanabe S; Kikuchi T; Hirose K; Kubota Y; Chihara Y; Harada T; Tanimura K; Takeda T; Tamiya N; Kaneko Y; Uchino J; Takayama K
Cancer Med; 2019 Apr; 8(4):1521-1529. PubMed ID: 30790471
[TBL] [Abstract][Full Text] [Related]
22. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
23. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
24. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Lin JJ; Chin E; Yeap BY; Ferris LA; Kamesan V; Lennes IT; Sequist LV; Heist RS; Mino-Kenudson M; Gainor JF; Shaw AT
J Thorac Oncol; 2019 Jan; 14(1):135-140. PubMed ID: 30205166
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.
Yamada Y; Imai H; Sugiyama T; Minemura H; Kanazawa K; Kasai T; Minato K; Kaira K; Kaburagi T
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577852
[No Abstract] [Full Text] [Related]
26. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
27. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995
[TBL] [Abstract][Full Text] [Related]
28. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
[TBL] [Abstract][Full Text] [Related]
29. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.
Tamura K; Nukiwa T; Gemma A; Yamamoto N; Mizushima M; Ochai K; Ikeda R; Azuma H; Nakanishi Y
Int J Clin Oncol; 2019 Aug; 24(8):917-926. PubMed ID: 30953238
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study.
Yu Y; Wang Y; Wu L; Xu X; Zhou H; Wang Q; Zhou J
Medicine (Baltimore); 2021 Feb; 100(5):e23712. PubMed ID: 33592829
[TBL] [Abstract][Full Text] [Related]
31. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
32. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
Yang L; Yang S; Liu Y; Li J; Hu X; Wang Y; Zhang Y; Wang Y
Thorac Cancer; 2018 Jun; 9(6):693-698. PubMed ID: 29655198
[TBL] [Abstract][Full Text] [Related]
33. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Baumann P; Langer CJ
Clin Lung Cancer; 2021 Jan; 22(1):49-57. PubMed ID: 33250347
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
38. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
[TBL] [Abstract][Full Text] [Related]
39. Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.
Yang X; Mei T; Yu M; Gong Y
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):409-419. PubMed ID: 35747920
[TBL] [Abstract][Full Text] [Related]
40. Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Cabeza Barrera J; Faus-Dáder MJ
Mutat Res Rev Mutat Res; 2019; 781():63-70. PubMed ID: 31416579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
